1. Executive Session 6:00 - 6:15
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes 6:15 - 6:20
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:20 - 6:30
   - Updates

4. Medical Director Update 6:30 - 6:35
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:35 – 6:50
   - Muscle Relaxants
   - Benzodiazepines

6. RetroDUR/DUR 6:50 – 7:00
   - Zolpidem Updated Dose Recommendations QA: Zolpidem Dosing Post FDA Safety Warning

7. Clinical Update: Drug Reviews 7:00 – 7:40
   (Public comment prior to Board action)

   Abbreviated New Drug Reviews
   - Desvenlafax ER (desvenlafaxine fumarate) Extended Release Oral Tablet

   Full New Drug Reviews
   - Duavee® (bazedoxifene/conjugated estrogens) Oral Tablet
   - Hetlioz® (tasimelteon) Oral Capsule
   - Orenitram® (treprostinil) Extended Release Oral Tablet
   - Otezla® (apremilast) Oral Tablet
8. Therapeutic Drug Classes – Periodic Review 7:40 – 7:40
   (Public comment prior to Board action)
   ▪ None

   (Public comment prior to Board action)
   ▪ Synagis® (see below)

10. New Managed Therapeutic Drug Classes 7:40 – 7:40
    (Public comment prior to Board action)
    ▪ None

11. Review of Newly-Developed/Revised 7:40 – 8:15
    Clinical Coverage Criteria and/or Preferred Products
    (Public comment prior to Board action)
    ▪ Pulmonary: Synagis®: New AAP Guidelines

       Updates for 1/1/2015
       ▪ Anti-emetics: NK1 Antagonists
       ▪ Anti-infectives: Antibiotics: Cephalosporins
       ▪ Cystic Fibrosis: Medications
       ▪ Dermatological Agents: Scabicides and Pediculocides
       ▪ Gastrointestinal: Inflammatory Bowel Agents (Oral/Rectal)
       ▪ Hepatitis C Agents
       ▪ Otic: Anti-infectives
       ▪ Testosterone: Topical
       ▪ Vitamins: Prenatal Vitamins

12. General Announcements 8:15– 8:15
    Selected FDA Safety Alerts
    ▪ None

13. Adjourn 8:15